Last reviewed · How we verify
Cord Blood Infusion
Cord Blood Infusion is a Biologic drug developed by Joanne Kurtzberg, MD. It is currently in Phase 2 development for Treatment of severe combined immunodeficiency (SCID), Treatment of leukemia and lymphoma, Treatment of other blood-related disorders. Also known as: Stem cell infusion.
Cord blood infusion involves the transfer of hematopoietic stem cells from the umbilical cord to a recipient to stimulate the production of new blood cells.
Cord blood infusion involves the transfer of hematopoietic stem cells from the umbilical cord to a recipient to stimulate the production of new blood cells. Used for Treatment of severe combined immunodeficiency (SCID), Treatment of leukemia and lymphoma, Treatment of other blood-related disorders.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Cord Blood Infusion |
|---|---|
| Also known as | Stem cell infusion |
| Sponsor | Joanne Kurtzberg, MD |
| Modality | Biologic |
| Therapeutic area | Hematology |
| Phase | Phase 2 |
Mechanism of action
This process can help to treat various blood-related disorders by replenishing the recipient's bone marrow with healthy stem cells. The exact mechanism of action is not fully understood, but it is believed to involve the engraftment of the donor stem cells into the recipient's bone marrow, leading to the production of new blood cells.
Approved indications
- Treatment of severe combined immunodeficiency (SCID)
- Treatment of leukemia and lymphoma
- Treatment of other blood-related disorders
Common side effects
- Graft-versus-host disease
- Infection
- Bleeding
Key clinical trials
- Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies (PHASE1)
- Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome (PHASE1, PHASE2)
- Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma (PHASE1)
- Study of Combined Decompressive Spine Radiosurgery and Pembrolizumab (EARLY_PHASE1)
- US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies (PHASE1, PHASE2)
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations (PHASE2)
- Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition
- US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cord Blood Infusion CI brief — competitive landscape report
- Cord Blood Infusion updates RSS · CI watch RSS
- Joanne Kurtzberg, MD portfolio CI
Frequently asked questions about Cord Blood Infusion
What is Cord Blood Infusion?
How does Cord Blood Infusion work?
What is Cord Blood Infusion used for?
Who makes Cord Blood Infusion?
Is Cord Blood Infusion also known as anything else?
What development phase is Cord Blood Infusion in?
What are the side effects of Cord Blood Infusion?
Related
- Manufacturer: Joanne Kurtzberg, MD — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Treatment of severe combined immunodeficiency (SCID)
- Indication: Drugs for Treatment of leukemia and lymphoma
- Indication: Drugs for Treatment of other blood-related disorders
- Also known as: Stem cell infusion
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing